| SpA with TB | SpA without TB | P value |
---|---|---|---|
NSAIDs | 43/43 (100.0%) | 2783/2926 (95.1%) | 0.14 |
glucocorticoid therapy > 6 months | 6/43 (14.0%) | 148/2926 (5.1%) | 0.01 |
DMARDs | 29/43 (67.4%) | 1831/2926 (62.6%) | 0.51 |
cDMARDs | 21/43 (48.8%) | 1609/2926 (55.0%) | 0.42 |
sulfasalazine | 16/43 (37.2%) | 1253/2926 (42.8%) | 0.46 |
methotrexate | 9/43 (20.9%) | 763/2926 (26.1%) | 0.45 |
leflunomide | 0/43 (0.0%) | 156/2926 (5.3%) | 0.12 |
bDMARDs | 17/43 (39.5%) | 709/2926 (24.2%) | 0.02 |
TNFi | 17/43 (39.5%) | 666/2926 (22.8%) | 0.001 |
infliximab | 10/43 (23.3%) | 98/2926 (3.3%) | < 0.001 |
etanercept | 2/43 (4.7%) | 268/2926 (9.2%) | 0.31 |
adalimumab | 5/43 (11.6%) | 235/2926 (8.0%) | 0.39 |
golimumab | 0/43 (0.0%) | 196/2926 (6.7%) | 0.08 |
certolizumab | 0/43 (0.0%) | 39/2926 (1.3%) | 0.45 |
secukinumab | 0/43 (0.0%) | 69/2926 (2.4%) | 0.31 |
ustekinumab | 0/43 (0.0%) | 19/2926 (0.6%) | 0.60 |